Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines

Haematologica

Volumn 90, Issue 11, 2005, Pages 1541-1548

  Verdelli, Donata ^a   Mattioli, Michela ^a   Fabris, Sonia ^a   Nobili, Lucia ^b   Intini, Daniela ^a   Guerneri, Silvana ^c   Todoerti, Katia ^a   Zanella, Alberto ^a   Deliliers, Giorgio Lambertenghi ^b   Lombardi, Luigia ^a   Neri, Antonino ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Laboratorio di Informatica Medica   (Italy)

Author keywords

Human myeloma cell lines; IL 6 dependent cell lines; Multiple myeloma

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER GENETICS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; MALE; MOLECULAR BIOLOGY; MULTIPLE MYELOMA; MYELOMA CELL; PATHOGENESIS; PLASMA CELL; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH;

AGED; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 27844482132     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
2. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003; 194:112-39.
3. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44.
4. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 2000;24:681-703.
5. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003; 4:557-64.
6. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994;24:1945-8.
7. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
8. Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, et al. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer 2005;42:117-27.
9. Fabris S, Storlazzi CT, Baldini L, Nobili L, Lombardi L, Maiolo AT, et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosomes Cancer 2003;37:261-9.
10. Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003;36:99-106.
11. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005;24:2461-73.
12. Califano A. SPLASH: structural pattern localization analysis by sequential histograms. Bioinformatics 2000;16:341-57.
13. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004;89:547-51.
14. San Miguel JF, Gonzalez M, Gascon A, Moro MJ, Hernandez JM, Ortega F, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991;77:185-90.
15. Omedé P, Boccadoro M, Fusaro A, Gallone G, Pileri A. Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br J Haematol 1993;85:504-13.
16. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:1977-82.
17. Kraj M, Poglod R, Kopec-Szlezak J, Sokolowska U, Wozniak J, Kruk B. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004;45: 2281-9.
18. Thabard W, Barille S, Collette M, Harousseau JL, Rapp MJ, Bataille R, et al. Myeloma cells release soluble interleukin-6Ra in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. Clin Cancer Res 1999;5: 2693-7.
19. Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, Barlogie B, et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 2005;42:95-106.
20. Moss ML, Bartsch JW. Therapeutic benefits from targeting of ADAM family members. Biochemistry 2004;43: 7227-35.
21. Klein B. Update of gp130 cytokines in multiple myeloma. Curr Opin Hematol 1998;5:186-91.
22. Claudio JO, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li ZH, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002;100:2175-86.
23. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.